Cargando…
Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
With an increasing aging population, the burden of age-related diseases magnifies. To alleviate this burden, geroprotection has been an area of intense research focus with the development of pharmacological interventions that target lifespan and/or healthspan. However, there are often sex difference...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249017/ https://www.ncbi.nlm.nih.gov/pubmed/37305228 http://dx.doi.org/10.3389/fragi.2023.1172789 |
_version_ | 1785055473243783168 |
---|---|
author | Knufinke, Marie MacArthur, Michael R. Ewald, Collin Y. Mitchell, Sarah J. |
author_facet | Knufinke, Marie MacArthur, Michael R. Ewald, Collin Y. Mitchell, Sarah J. |
author_sort | Knufinke, Marie |
collection | PubMed |
description | With an increasing aging population, the burden of age-related diseases magnifies. To alleviate this burden, geroprotection has been an area of intense research focus with the development of pharmacological interventions that target lifespan and/or healthspan. However, there are often sex differences, with compounds mostly tested in male animals. Given the importance of considering both sexes in preclinical research, this neglects potential benefits for the female population, as interventions tested in both sexes often show clear sexual dimorphisms in their biological responses. To further understand the prevalence of sex differences in pharmacological geroprotective intervention studies, we performed a systematic review of the literature according to the PRISMA guidelines. Seventy-two studies met our inclusion criteria and were classified into one of five subclasses: FDA-repurposed drugs, novel small molecules, probiotics, traditional Chinese medicine, and antioxidants, vitamins, or other dietary supplements. Interventions were analyzed for their effects on median and maximal lifespan and healthspan markers, including frailty, muscle function and coordination, cognitive function and learning, metabolism, and cancer. With our systematic review, we found that twenty-two out of sixty-four compounds tested were able to prolong both lifespan and healthspan measures. Focusing on the use of female and male mice, and on comparing their outcomes, we found that 40% of studies only used male mice or did not clarify the sex. Notably, of the 36% of pharmacologic interventions that did use both male and female mice, 73% of these studies showed sex-specific outcomes on healthspan and/or lifespan. These data highlight the importance of studying both sexes in the search for geroprotectors, as the biology of aging is not the same in male and female mice. Systematic Review Registration: [website], identifier [registration number]. |
format | Online Article Text |
id | pubmed-10249017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102490172023-06-09 Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review Knufinke, Marie MacArthur, Michael R. Ewald, Collin Y. Mitchell, Sarah J. Front Aging Aging With an increasing aging population, the burden of age-related diseases magnifies. To alleviate this burden, geroprotection has been an area of intense research focus with the development of pharmacological interventions that target lifespan and/or healthspan. However, there are often sex differences, with compounds mostly tested in male animals. Given the importance of considering both sexes in preclinical research, this neglects potential benefits for the female population, as interventions tested in both sexes often show clear sexual dimorphisms in their biological responses. To further understand the prevalence of sex differences in pharmacological geroprotective intervention studies, we performed a systematic review of the literature according to the PRISMA guidelines. Seventy-two studies met our inclusion criteria and were classified into one of five subclasses: FDA-repurposed drugs, novel small molecules, probiotics, traditional Chinese medicine, and antioxidants, vitamins, or other dietary supplements. Interventions were analyzed for their effects on median and maximal lifespan and healthspan markers, including frailty, muscle function and coordination, cognitive function and learning, metabolism, and cancer. With our systematic review, we found that twenty-two out of sixty-four compounds tested were able to prolong both lifespan and healthspan measures. Focusing on the use of female and male mice, and on comparing their outcomes, we found that 40% of studies only used male mice or did not clarify the sex. Notably, of the 36% of pharmacologic interventions that did use both male and female mice, 73% of these studies showed sex-specific outcomes on healthspan and/or lifespan. These data highlight the importance of studying both sexes in the search for geroprotectors, as the biology of aging is not the same in male and female mice. Systematic Review Registration: [website], identifier [registration number]. Frontiers Media S.A. 2023-05-22 /pmc/articles/PMC10249017/ /pubmed/37305228 http://dx.doi.org/10.3389/fragi.2023.1172789 Text en Copyright © 2023 Knufinke, MacArthur, Ewald and Mitchell. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Aging Knufinke, Marie MacArthur, Michael R. Ewald, Collin Y. Mitchell, Sarah J. Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review |
title | Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review |
title_full | Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review |
title_fullStr | Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review |
title_full_unstemmed | Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review |
title_short | Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review |
title_sort | sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review |
topic | Aging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249017/ https://www.ncbi.nlm.nih.gov/pubmed/37305228 http://dx.doi.org/10.3389/fragi.2023.1172789 |
work_keys_str_mv | AT knufinkemarie sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview AT macarthurmichaelr sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview AT ewaldcolliny sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview AT mitchellsarahj sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview |